Press Release 2

Irving, Texas (July 11, 2007) – The Journal of the American Society of Clinical Oncology has published the early results of a clinical study conducted by Dr. Siu-Fun Wong, and her colleagues, which concluded that the topical gel, Regenecare®, caused a statistically significant reduction in the pain and itching of a rash that results from the use of anti-cancer drugs known as EGFR inhibitors. This ongoing supportive care trial is listed on the National Cancer Institute Clinical Trials website (www.cancer.gov).

Paul Miller, President of MPM Medical, stated "EGFR inhibitors form a group of drugs, sold by several pharmaceutical companies, which are effective in the treatment of cancer. However, after a few weeks of use, an acne-like rash often appears on the face, neck, back, hands, and/or legs resulting in severe pain and itching for the patient. We know of no other evidence-based topical applications reported in the scientific literature shown to help manage rash symptoms caused by EGFR drugs."

MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (RBCL OTC:BB), announced the initiation of human clinical trials, in three medical institutions, designed to evaluate the efficacy of its topical wound gel, Regenecare™, in the relief of painful, itching skin rashes that occur as a side effect during treatment by a group of widely-used cancer drugs known as epidermal growth factor receptor (EGFR) inhibitors.

EGFR drugs are marketed by several pharmaceutical companies under various trade names. They are used to treat cancers of the head, neck, gastric tract, lungs and pancreas. However, within a few weeks of use, a majority of patients develop painful, itching, red skin rashes on the face, chest, and back. A number of physicians reported to MPM that when they applied Regenecare to the rash areas three to four times per day, the side effects of EGFR drugs were significantly reduced. Based on these physician reports, MPM is sponsoring the double-blind human clinical trials, results of which are expected to be submitted for publication in peer reviewed journals later this year.

Paul Miller, President of MPM said, "Preliminary results in one 20 patient study have shown statistically significant reduction of pain and itching after applying Regenecare to the rash area. These results were presented last week in California at the Ninth National Research Conference of the Oncology Nurses Society."

MPM Medical, Inc. develops and markets a proprietary line of research-based wound care products.

Regenecare® is a proprietary product of MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (RBCL OTC:BB).

MPM Medical develops and markets a line of prescription and nonprescription products for wound management, through medical-surgical dealers, to nursing homes, hospitals, and cancer clinics.